Nicole Lou is a Medical Reporter at MedPage Today. She specializes in medicine and healthcare, with a focus on medical specialties such as endocrinology, oncology, and surgery. Nicole's work has been featured in MedPage Today, MSN, Knowledia, and RamaOnHealthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Nicole Lou's coverage heavily focuses on healthcare and pharmaceuticals, particularly topics related to cardiac health, medical research, treatments, and controversies in the healthcare industry. Her articles often cite data extensively.
She would likely welcome pitches that offer access to new or exclusive data related to developments in cardiac health, medical research breakthroughs or controversies within the healthcare industry. Additionally, she may be interested in expert commentary from professionals with direct experience or involvement in the subjects covered.
Given her focus on citing data extensively, sources who can provide robust and reliable statistics as well as evidence-based insights will be of particular interest to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Nicole Lou
— Recent developments of interest in cardiovascular medicine Cardiologist Lisa Nee, MD opens in a new tab or window -- who was also a former
By: Nicole Lou
Quantitative volumetry better avoids futile reperfusion, per a nationwide study
There was evidence for going beyond the Alberta Stroke Program Early CT Score (ASPECTS) in selecting stroke patients with enough salvageable brain tissue to benefit from thrombectomy, one group contended.
Natural history study probes predictors of worsening in mild disease
If therapies were to expand to people with mild hypertrophic cardiomyopathy (HCM), the first in line should be specific groups more prone to disease worsening, suggested one registry study.
Quality-of-life effects still a major unknown, researchers say
Nicole Lou Variable weight-loss and cardiovascular benefits were seen with GLP-1 drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear.
— Painful event can cause internal bleeding, block the flow of blood from the heart to other organs
By: Nicole Lou
Key Takeaways A randomized trial tested once-daily thromboprophylaxis with aspirin or rivaroxaban for the first 5 days after total hip or total knee arthroplasty, followed by aspirin alone.
By: Nicole Lou
A multisociety expert consensus statement calls for wider implementation of enhanced radiation protection devices for cath lab operators opens in a new tab or window JACC: Cardiovascular Interventions
